Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-28T23:32:24.761Z Has data issue: false hasContentIssue false

Expanding Access to Naloxone: A Necessary Step to Curb the Opioid Epidemic

Published online by Cambridge University Press:  29 September 2022

Ryan Houser*
Affiliation:
Boston University School of Medicine, Boston, MA, USA
*
Corresponding author: Ryan Houser, Email: houser.ryanscott@gmail.com.

Abstract

The COVID-19 Pandemic has exacerbated the already worsening opioid epidemic within the United States. With a continuing increase in opioid overdose deaths, measures are needed to halt the needless number of deaths and begin on a path of recovery to address all the factors that impact the epidemic. The CDC has provided various recommendations to combat the increases in opioid overdose deaths. These recommendations have included expanded distribution and use of naloxone and overdose prevention education as essential services for people most at risk of overdose. While strategies should include the increase in community resources for those with opioid disorder and shifting the perspectives of healthcare to view opioid disorder as a chronic illness that can be treated with medication such as buprenorphine, these methods are not immediate enough to stop the trend in deaths. The United States must take immediate action to expand access to and use of Naloxone for the public and first responders. Naloxone alone cannot address the magnitude of this epidemic, but it is an essential first step in preventing immediate death while a multimodal strategy is enacted to fully protect those most at risk.

Type
Concepts in Disaster Medicine
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Overdose Deaths Accelerating During COVID-19. Centers for Disease Control and Prevention (CDC). Published December 18, 2020. Accessed June 10, 2021. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html Google Scholar
Weiner, J, Murphy, SM, Behrends, C. Expanding access to naloxone: a review of distribution strategies. Leonard Davis Institute of Health Economics (Penn LDI). Published May 29, 1970. Accessed June 10, 2021. https://ldi.upenn.edu/brief/expanding-access-naloxone-review-distribution-strategies Google Scholar
Sharpless, N. Statement on continued efforts to increase availability of all forms of naloxone to help reduce opioid overdose deaths. US Food and Drug Administration. Published September 20, 2019. Accessed June 10, 2021. https://www.fda.gov/news-events/press-announcements/statement-continued-efforts-increase-availability-all-forms-naloxone-help-reduce-opioid-overdose Google Scholar
FDA Briefing Document Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee December 17–18, 2018. FDA. Published December 2020. Accessed June 10, 2021. https://www.fda.gov/media/121182/download Google Scholar
Life-Saving Naloxone from Pharmacies. Centers for Disease Control and Prevention (CDC). Published August 6, 2019. Accessed June 16, 2021. https://www.cdc.gov/vitalsigns/naloxone/index.html Google Scholar
Freeman, PR, Hankosky, ER, Lofwall, MR, Talbert, JC. The changing landscape of naloxone availability in the United States, 2011–2017. Drug Alcohol Depend. 2018;191:361-364. doi: 10.1016/j.drugalcdep.2018.07.017 Google ScholarPubMed
Chang, HY, Kharrazi, H, Bodycombe, D, et al. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Med. 2018;16(1):69. doi: 10.1186/s12916-018-1058-y Google ScholarPubMed
Naloxone for Opioid Overdose: Life-Saving Science. National Institute on Drug Abuse. Published June 2, 2021. Accessed June 10, 2021. https://www.drugabuse.gov/publications/naloxone-opioid-overdose-life-saving-science#ref Google Scholar
Follman, S, Arora, VM, Lyttle, C, et al. Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose. JAMA Netw Open. 2019;2(5):e193209.Google ScholarPubMed
State Naloxone Access Rules and Resources. Safe Project US. Published 2022. https://www.safeproject.us/naloxone-awareness-project/state-rules/. Accessed May 10, 2022.Google Scholar
Abouk, R, Pacula, RL, Powell, D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 2019;179(6):805-811. doi: 10.1001/jamainternmed.2019.0272.CrossRefGoogle ScholarPubMed
Puzantian, T, Gasper, JJ. Provision of naloxone without a prescription by California pharmacists 2 years after legislation implementation. JAMA. 2018;320(18):1933-1934.Google ScholarPubMed
Graves, RL, Andreyeva, E, Perrone, J, et al. Naloxone availability and pharmacy staff knowledge of standing order for naloxone in Pennsylvania pharmacies. J Addict Med. 2018;13(4):272-278. doi: 10.1097/ADM.0000000000000492.Google Scholar
Correal, A. Overdose antidote is supposed to be easy to get. It’s not. New York Times. Published April 12, 2018. Accessed June 16, 2021. https://www.nytimes.com/2018/04/12/nyregion/overdose-antidote-naloxone-investigation-hard-to-buy.html Google Scholar
Healthcare, Hennepin. Information about naloxone. Hennepin Healthcare. https://www.hennepinhealthcare.org/patient-care/pharmacy/naloxone/. Published June 22, 2020. Accessed June 16, 2021.Google Scholar
Townsend, T, Blosteina, F, Doana, T, et al. Cost-effectiveness analysis of alternative naloxone distribution strategies: first responder and lay distribution in the United States. Int J Drug Policy. 2019;75:102536. doi: 10.1016/j.drugpo.2019.07.031.Google ScholarPubMed
Darke, S, Mattick, RP, Degenhardt, L. The ratio of non-fatal to fatal heroin overdose. Addiction. 2003;98(8):1169-1171.CrossRefGoogle ScholarPubMed
Osterwalder, JJ. Naloxone–for intoxications with intravenous heroin and heroin mixtures—harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol. 1996;34(4):409-416.CrossRefGoogle ScholarPubMed
Is Naloxone (Narcan®) Sold Over-the-Counter? Health Essentials from Cleveland Clinic. Cleveland Clinic. Published October 8, 2020. Accessed June 16, 2021. https://health.clevelandclinic.org/is-naloxone-narcan-sold-over-the-counter/ Google Scholar